Interim Report – January to June 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter 2018.

Financial Highlights

• Revenue for the 2nd Quarter 2018 amounted to SEK 36.9 (26.2) m, and to 59.5 (57.4) m for the full six-month period
• Operating result for the quarter amounted to SEK -8.8 (-19.7) m, and to -45.8 (-17.4) m for the full six-month period
• Net result for the quarter amounted to SEK -8.7 (-19.6) m, and to -45.7 (-17.3) m for the full six-month period
• Cash flow for the quarter amounted to SEK -63.2 (-54.2) m, and to -54.6 (-36.2) m for the full six-month period
• Cash and cash equivalents at the end of the period amounted to SEK 186.7 (90.9) m.

Significant Events during the Reporting Period

• A Clinical Trial Application (CTA) for a multicenter investigator led clinical Phase II/III study with [68Ga] ABY-025 in Sweden, Denmark and Finland, was submitted in April, 2018 to the Medical Product Agency (MPA)

Significant Events during the rest of the Year

• A 100 patient multicenter Phase II study of ABY-035 in Germany, commenced in March 2018
• A Phase I proof-of-principle study of ABY-039 in the UK, commenced in March 2018
• The rights issue of shares resolved at the EGM on November 23, completed in January, was fully subscribed for with corresponding proceeds of SEK 199m.